- Dexcom ONE+ is now available in the UK, incorporating 25 years
of Dexcom research to offer a sensor that better meets the needs of
those living with diabetes.
- Dexcom’s first-ever State of Type 2 Report features survey
findings from people with Type 2 diabetes and reveals majority of
respondents struggle with anxiety and depression1.
- The ‘Dexcom State of Type 2 Report’ also shows 54% of people
wish they could gain more confidence in managing their Type 2
diabetes1.
- CGM usage amongst people with Type 2 diabetes can lead to
greater user motivation and improved diabetes management2.
DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time
continuous glucose monitoring (CGM) for people with diabetes, today
announced both the launch of Dexcom ONE+, a CGM device that easily
tracks real-time glucose readings to help improve diabetes
management, and the Dexcom State of Type 2 Report. The report is a
first-of-its-kind look at the Type 2 landscape today and examines
the preferences and behaviours of those living with the condition,
as well as their caretakers and healthcare professionals. It is
hoped that the report will serve as a valuable resource for
healthcare professionals supporting those living with Type 2
diabetes and empower those with Type 2 to feel less isolated.
Additionally, Dexcom ONE+ can offer a diabetes management solution
specifically suited to those living with Type 2 diabetes.
As the UK observes Type 2 Diabetes Prevention Week, the
first-ever State of Type 2 Report, from Dexcom, discovered that
nearly half (49%) of individuals with Type 2 diabetes were unaware
of the condition’s effects when diagnosed. Now, 63% are
encountering difficulties in managing their diabetes, including
challenges related to improving their diet or their mental health,
in fact 42% of people with diabetes and caregivers surveyed say
living with Type 2 has negatively impacted their mental health or
that of the person they care for, of those respondents anxiety
(61%) and depression (52%) are the most commonly reported effects
of living with Type 2 diabetes . Furthermore, when asked, close to
half (48%) believe that being able to monitor their glucose levels
would help them better manage their condition, while 39% feel that
greater knowledge about available care options would be
beneficial.
However, the good news for those struggling to manage Type 2
diabetes is that a recent study2 has shown a link between real-time
CGM usage, such as Dexcom ONE+, and improved management of the
condition. The study showed that by bringing awareness to the
impact of food and exercise choices on an individual’s glucose
levels, people became more motivated to continue making positive
choices, likely leading to significant glycaemic benefits2.
“The Dexcom State of Type 2 report reveals that people trying to
manage their Type 2 diabetes face significant impacts on all areas
of their lives including, and perhaps particularly, their mental
health,” says Karen Baxter, Vice President, Northern Europe, South
Africa, Israel, and Malta at Dexcom. “We’re proud to have developed
a sensor that addresses the unmet needs of the Type 2 community.
Feedback from users and healthcare professionals already using
Dexcom ONE+ indicates that the sensor is easy to use and
motivational, as it provides a clearer understanding of how food
and exercise choices affect glucose levels. Seeing real-time
feedback can help alleviate the frustration many people, especially
those with Type 2 diabetes, experience in understanding and
managing their condition.”
About Dexcom ONE+
Dexcom ONE+ incorporates 25 years of Dexcom's research into
real-time CGM and the unique needs of different diabetes
communities. Developed based on feedback from consumers and
healthcare professionals from the previous generation Dexcom ONE
sensor the result is a more flexible and easier‖,4,† to use CGM
system, better suited to the needs of those managing Type 2
diabetes, whilst also improving the sensor experience for those
living with Type 1.
For people managing diabetes using fingerpricks and regularly
injecting insulin, their lives can feel overwhelmed by diabetes.
Dexcom ONE+ was developed to take away some of this burden, it’s
easy to get started with** and is designed to be easy to live with,
even for those with no experience of using a CGM system. Like all
Dexcom CGM, Dexcom ONE+ gives a clear picture of what glucose
levels are doing in real-time, without painful fingerpricks*,
therefore making it easier‖ for people to achieve lasting
results§,5,‡‡,7,8. Importantly, for loved ones, Dexcom ONE+ also
allows a user to easily share their glucose numbers with up to ten
people, offering everyone a little more peace of mind††.
Features that set Dexcom ONE+ apart from other CGM systems
include multiple possibilities for personalisation and flexibility.
Dexcom CGM systems also offer the most discretion, with three wear
location options‡ 3,6 and are the only CGM systems to offer a
‘delay first high’ option3§§, a customisable feature which allows a
user to set a time before which their sensor will not alert them to
a ‘high’ glucose reading, helping to avoid alert fatigue and
rebound hypoglycaemia due to over treatment^,9. Furthermore,
designed to fit seamlessly into a user’s life, Dexcom ONE+ also has
the highest waterproof rating when compared to other CGM brands,
allowing users to confidently continue using their device while
showering or exercising.
Dexcom ONE+ is suitable for people living with both Type 1 and
Type 2, is covered for some people on prescription via the NHS and
is also available to purchase online. People living with diabetes
and caregivers should speak to their doctor about the best options
for them.
More on the Dexcom State of Type 2 Report
More than five million people in the UK are living with diabetes
– and 90% of this group have Type 2, according to Diabetes UK. The
first-of-its-kind Dexcom State of Type 2 Report was designed to
offer insights into the realities of living with the condition.
“As the State of Type 2 Report reveals, living with Type 2
diabetes can come with psychological as well as physical
challenges,” says Dr. Rose Stewart, Consultant Clinical
Psychologist and chair of the UK Diabetes Psychology Network. “Many
people living with Type 2 diabetes feel like they don’t understand
their condition, and feel like it is beyond their control – this
combination of issues can contribute to more problems managing
diabetes and detrimental mental health challenges. Fortunately,
with tech advancements, people living with Type 2 can now feel
empowered to better understand their condition, feel like they can
manage it effectively and live more confidently. Using technology
like a CGM paired with health boosting activities – whether that be
exercise, relaxation, enjoying time with loved ones or something
else –can help people confidently tackle type 2 along with the
stresses it creates every day.”
Specific findings include:
- Understanding at Diagnosis: Just 10% of patients and
their caregivers know a lot about Type 2 before diagnosis.
- Mental Health Challenges: Nearly half (42%) of patients
and caregivers surveyed said that living with type 2 has negatively
impacted their mental health, or that of the person they care
for.
- Technological Advancements: While only 9% of patients
and caregivers fully understand what a CGM system is – and 70% are
unaware it's available on prescription for some people with type 2
– most know that it will help improve their lives with diabetes: in
fact, 40% say being able to see glucose numbers in real time and
having access to CGM would have the most positive effect on their
type 2 diabetes or that of the person they care for.
To read the Dexcom State of Type 2 Report and learn more about
how Dexcom ONE+ can benefit you or your loved one, visit
dexcom.com/t2report. Dexcom ONE+ will replace the current Dexcom
ONE sensor.
Notes to Editors
Additional context, findings, and key highlights from the Dexcom
State of Type 2 Report include:
Understanding at Diagnosis: Awareness of type 2 diabetes
is low prior to diagnosis, with just 10% of patients knowing a lot
about type 2 before diagnosis. Once diagnosed, healthcare
practitioners find that patients are most concerned with long-term
complications (29%), fear of diabetes related health issues (28%)
and how much it will impact their day-to-day lives (27%).
Mental Health Challenges: Living with type 2 diabetes
takes a toll on mental health. Nearly half (42%) of patients and
caregivers surveyed said that living with type 2 has negatively
impacted their mental health, or that of the person they care for.
Anxiety (61%) and depression (52%) are the most commonly reported
effects of living with type 2.
Balancing Nutrition: Patients and caregivers recognise
the importance of proper nutrition to manage type 2, with 81%
saying they are aware eating healthily would positively affect
their diabetes. Still, there’s room for education and excitement
when it comes to eating, with over a quarter (27%) of patients and
caregivers agreeing they don’t think they have the right education
on food, and 39% saying they find eating after their type 2
diagnosis boring.
Technological Advancements: Technology like CGM makes it
easy to manage type 2 diabetes. While only 9% of patients and
caregivers fully understand what a CGM system is – and 70% are
unaware it's available on prescription for some people with type 2
– most know that it will help improve their lives with diabetes: in
fact, 40% say being able to see glucose numbers in real time and
having access to CGM would have the most positive effect on their
type 2 diabetes or that of the person they care for. Additionally,
83% of patients say if their healthcare team offered them a CGM
they would try it.
The Future of Type 2 Diabetes: Sixty-two percent of
healthcare practitioners expect the number of patients diagnosed
with type 2 diabetes will increase in the next 10 years – with 97%
anticipating CGM will become standard practice for caring for
patients with type 2 diabetes.1
Will Dexcom ONE+ replace the current Dexcom ONE?
Dexcom ONE+ has been developed based on feedback from consumers
and healthcare professionals from the previous generation Dexcom
ONE sensor. Patients currently using Dexcom ONE will be
transitioned once Dexcom ONE+ is available in their area, so they
can benefit from this new and improved generation of Dexcom
sensor.
About DexCom, Inc.
DexCom, Inc. empowers people to take real-time control of health
through innovative continuous glucose monitoring (CGM) systems.
Headquartered in San Diego, Calif., and with operations across
Europe, Dexcom has emerged as a leader of diabetes care technology.
By listening to the needs of users, caregivers, and providers,
Dexcom works to simplify and improve diabetes management around the
world. For more information about Dexcom CGM, visit
www.dexcom.com.
Methodology
The research was conducted in March 2024 by Censuswide on behalf
of Dexcom with 501 UK respondents who are living with T2 diabetes
or caring for someone who does, 250 people with diabetes (min 50
using insulin – ‘Type 2 IIT’) AND 250 caregivers, family members,
etc., of people with diabetes, AND 351 (Age 21+) HCPs involved in
the care of people with T2 diabetes, including at least 50 people
in each primary care job title and 50 overall for the secondary
care job titles, including min 50 who see patients using insulin –
‘Type 2 IIT’. Censuswide abide by and employ members of the Market
Research Society which is based on the ESOMAR principles and are
members of The British Polling Council.
1 Dexcom and Censuswide online survey of people living with
diabetes (Type 2, their caretakers and healthcare practitioners),
conducted in the UK, H1 2024, N=852, PWD = 251, HCP = 351,
Caretakers = 250. 2 Clark T et al. Diabetes Technol Ther. 2024.
doi: 10.1089/dia.2023.0612. 3 Dexcom ONE+ User Guide, 2023. 4
Dexcom Data on file 2022, G7 UK Limited Launch Survey, N= 100. 5
Lind M, et al. Diabetes Care. 2021;44(1):141-149. 6 Freestyle Libre
2, Medtronic and Senseonics User Guides. 7 Soupal J, et al.
Diabetes Care. 2020; 43: 37-43. 8 Lind M, et al. Diabetes Care.
2021;44(1):141-149. 9 Wilmot, E. “Dexcom G7. Unique Features and
Correlational Improvements in Glycemic Control.” Presented at the
16th International Conference on Advanced Technologies &
Treatments for Diabetes (ATTD) on February 23, 2023.
† Results obtained with Dexcom G7, which shares the similar
features and usability * If the glucose alerts and readings do not
match symptoms a blood glucose meter should be used to make
diabetes treatment decisions. ** Compared to previous generation
Dexcom CGM System, Dexcom ONE ‖ Compared to Blood Glucose Meter
patient use § Previous generation Dexcom CGM used, Dexcom ONE+ uses
the same sensor as G7 ‡‡ Study included non-Dexcom CGM system ‡
Dexcom ONE+ is approved for wear on the arm and abdomen, and
children 2-6 years can also wear their sensor on the upper buttocks
The Dexcom ONE+ Sensor is waterproof and may be submerged under 2.4
Meters of water for up to 24 hours without failure when properly
installed. †† Separate Follow app and internet connection required
^ RWE analysis derived from a pseudonymised, aggregated and/or
anonymous data set of Dexcom G7 users in the UK and EU. §§ Not
available with Dexcom G6
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240520447830/en/
Allison for Dexcom, DexcomUK@allisonworldwide.com
DexCom (NASDAQ:DXCM)
Gráfica de Acción Histórica
De Ago 2024 a Sep 2024
DexCom (NASDAQ:DXCM)
Gráfica de Acción Histórica
De Sep 2023 a Sep 2024